JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Chiusa

SettoreSettore sanitario

16.76 0.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

16.4

Massimo

16.95

Metriche Chiave

By Trading Economics

Vendite

132M

160M

Dipendenti

627

EBITDA

126M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+79.11% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

882M

1.9B

Apertura precedente

15.8

Chiusura precedente

16.76

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Arcus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 ott 2025, 20:49 UTC

Utili

Correction to Thermo Fisher Article on Oct. 22

23 ott 2025, 23:51 UTC

Discorsi di Mercato

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 ott 2025, 23:37 UTC

Discorsi di Mercato

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 ott 2025, 22:58 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

23 ott 2025, 22:57 UTC

Discorsi di Mercato

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 ott 2025, 22:17 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 ott 2025, 21:41 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 ott 2025, 21:05 UTC

Utili

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 ott 2025, 20:35 UTC

Utili

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 ott 2025, 20:28 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 ott 2025, 20:15 UTC

Discorsi di Mercato
Utili

Global Commodities Roundup: Market Talk

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Adj EPS $1.71

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Sales $5.52B

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q EPS $1.67

23 ott 2025, 20:09 UTC

Utili

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 ott 2025, 20:07 UTC

Utili

Blackstone Looks to IPOs for Investment Exits -- Update

23 ott 2025, 20:05 UTC

Utili

Intel 3Q Gross Margin 38.2% >INTC

23 ott 2025, 20:04 UTC

Utili

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 ott 2025, 20:04 UTC

Utili

Intel: 4Q Guidance Excludes Altera >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Sees 4Q Adj EPS 8c >INTC

Confronto tra pari

Modifica del prezzo

Arcus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

79.11% in crescita

Previsioni per 12 mesi

Media 32.33 USD  79.11%

Alto 54 USD

Basso 14 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

11

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.01 / 8.75Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat